Please assess the completion status of the following clinical trial:

Trial Title: Tirofiban for Patients Treated With Alteplase

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18~* Ischemic stroke symptom with onset ≤4.5 hours treated with IV rt-PA according with local guidelines.~* 6≤ NIHSS ≤20 before IV tPA, or NIHSS \>20 but decrease ≥ 8 after IV rt-PA.~* ≥ 4 point total NIHSS or ≥ 2 point in one NIHSS category during and after the IV rt-PA compared to immediately before worsening, an emergency CT scan should be performed to exclude intracranial hemorrhage~* Patients or their legally acceptable representative agreed to the treatment and signed the informed consent form~Exclusion Criteria:~* Patients whom the treating physician is planning to treat with mechanical thrombectomy or other endovascular procedure (e.g. Intra-arterial thrombolysis) according with local guidelines.~* Patients had used antiplatelet therapy in the past 5 days before the stroke.~* Patients had used anticoagulant therapy in the past 5 days before the stroke.~* Scheduled for surgery or interventional treatment requiring study drug cessation.~* CT scan finding of hypoattenuation involving ≥1/3 of the MCA territory.~* Any evidence of clinically significant bleeding ,or known coagulopathy.~* Renal insufficiency (creatinine clearance rate \<30ml/min)~* Hepatic dysfunction (ALT \>2 folds of Upper limit of normal value or AST\>2 folds of Upper limit of normal value).~* Pre-existing disability with ≥ mRS 2.~* Known allergic to tirofiban or other glycoprotein IIb/IIIa antagonist.~* Severe non-cerebrovascular disease with life expectancy \<3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tirofiban and alteplase (Type: EXPERIMENTAL): None
- Alteplase (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).